Lupin receives FDA nod for generic Atrovent
Ipratropium bromide nasal solution 0.06% is indicated for symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged five years and older.
Lupin has received approval from the Food and Drug Administration for ipratropium bromide nasal solution (nasal spray), 0.06%, which is a generic of Boehringer Ingelheim's Atrovent Nasal Spray, 0.06%.
The product will be manufactured at Lupin’s Pithampur facility in India.
[Read more: Lupin receives FDA OK for generic Banzel]
Ipratropium bromide nasal solution (Nasal Spray), 0.06% is indicated for symptomatic relief of rhinorrhea (runny nose) associated with the common cold or seasonal allergic rhinitis for adults and children aged five years and older.
Ipratropium bromide nasal solution (Nasal Spray), 0.06% (RLD Atrovent) had a market value of roughly $42 million, per IQVIA November 2024 data.
[Read more: Lupin launches generic Minzoya]
